Annexon Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Annexon wird ein Gewinn- und Umsatzwachstum von 35.6% bzw. 75.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 39.6% pro Jahr wachsen soll.

Wichtige Informationen

35.6%

Wachstumsrate der Gewinne

39.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	75.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Sep 27

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 04

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Sep 16

Annexon: A First Take

Aug 21

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Aug 08

Annexon to raise $130M in stock and warrant offering

Jul 08

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Apr 16

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Jan 01

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Sep 08

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

May 22

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Feb 06

Dosing underway in Annexon's Phase 2/3 study of monoclonal antibody in Guillain-Barré Syndrome

Dec 21

Annexon Biosciences EPS misses by $0.43

Nov 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ANNX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	54	-149	-119	-162	6
12/31/2025	11	-159	-136	-177	7
12/31/2024	N/A	-127	-129	-95	7
9/30/2024	N/A	-118	-105	-105	N/A
6/30/2024	N/A	-115	-102	-102	N/A
3/31/2024	N/A	-121	-116	-116	N/A
12/31/2023	N/A	-134	-121	-121	N/A
9/30/2023	N/A	-141	-125	-125	N/A
6/30/2023	N/A	-143	-128	-127	N/A
3/31/2023	N/A	-145	-120	-119	N/A
12/31/2022	N/A	-142	-123	-116	N/A
9/30/2022	N/A	-145	-125	-117	N/A
6/30/2022	N/A	-145	-124	-116	N/A
3/31/2022	N/A	-140	-120	-113	N/A
12/31/2021	N/A	-130	-108	-106	N/A
9/30/2021	N/A	-116	-98	-97	N/A
6/30/2021	N/A	-103	-81	-81	N/A
3/31/2021	N/A	-84	-67	-67	N/A
12/31/2020	N/A	-70	-54	-53	N/A
9/30/2020	N/A	-56	-43	-43	N/A
6/30/2020	N/A	-45	-36	-36	N/A
3/31/2020	N/A	-42	-33	-32	N/A
12/31/2019	N/A	-38	-29	-28	N/A
9/30/2019	N/A	-34	-25	-24	N/A
6/30/2019	N/A	-28	-21	-21	N/A
3/31/2019	N/A	-23	-19	-19	N/A
12/31/2018	N/A	-18	-17	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ANNX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ANNX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ANNX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ANNXDie Einnahmen des Unternehmens (75.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: ANNXDie Einnahmen des Unternehmens (75.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ANNX in 3 Jahren voraussichtlich hoch sein wird

Annexon Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 13% to US$16.40

Price target increased by 9.0% to US$15.17

Price target increased by 10% to US$15.60

Price target increased by 9.0% to US$15.33

Price target decreased by 18% to US$15.43

Price target decreased to US$18.71

Recent updates

CEO, President & Director exercised options to buy US$833k worth of stock.

Annexon, Inc. to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely

Annexon, Inc. Announces Management Appointments

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon, Inc. Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Price target increased by 13% to US$16.40

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Annexon, Inc. Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

New major risk - Share price stability

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon, Inc. Presents New Neuro Protection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy

Annexon, Inc., Annual General Meeting, Jun 05, 2024

Annexon: Unforced Error Sullies Prospects

Price target increased by 9.0% to US$15.17

Annexon, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Insider selling

New major risk - Share price stability

Executive VP notifies of intention to sell stock

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

Annexon, Inc. has completed a Follow-on Equity Offering in the amount of $125.01642 million.

New major risk - Revenue and earnings growth

Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation

New minor risk - Market cap size

Price target increased by 10% to US$15.60

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$15.33

Annexon, Inc. Appoints Jamie Dananberg as Chief Medical Officer

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Price target decreased by 18% to US$15.43

Annexon, Inc. Announces Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function

Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?

Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?

Annexon, Inc. Highlights Strategic Focus to Advance Four Complement Programs Through Late-Stage Development and Progress Across Three Therapeutic Franchises

Annexon, Inc. Announces Executive Changes

We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully

Price target decreased to US$18.71

Annexon started as a buy at Jefferies on market potential of candidates, data catalysts

Annexon: A First Take

Price target decreased to US$24.25

Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02

Annexon, Inc. announced that it has received $130.475296 million in funding from a group of investors

Annexon, Inc. announced that it expects to receive $130.475296 million in funding from a group of investors

Annexon to raise $130M in stock and warrant offering

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Index

Annexon, Inc. Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’S Disease

Price target decreased to US$30.80

CEO, President & Director recently bought US$147k worth of stock

We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate

Price target decreased to US$30.80

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

Price target decreased to US$34.20

Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer

Annexon, Inc. Announces Resignation of Ricky Sun as Board Member

Annexon, Inc. Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

CEO, President & Director exercised options to buy US$1.5m worth of stock.

Executive VP & Chief Scientific Officer Ted Yednock has left the company

Executive VP & Chief Scientific Officer exercised options and sold US$297k worth of stock

Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

Annexon, Inc Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

Annexon, Inc.(NasdaqGS:ANNX) dropped from Russell 2500 Growth Index

Executive VP & CFO exercised options and sold US$52k worth of stock

We Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business Growth

Annexon, Inc. Announces Executive Changes

Independent Director has left the company